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Objectives: To investigate and establish the prevalence of dementia with Lewy body (DLB) symptoms in
all nursing home (NH) residents in Malmö, the third largest city in Sweden. DLB is a neurocognitive
disorder with core features, such as parkinsonism, visual hallucinations, and ﬂuctuating cognition/
excessive daytime sleepiness, and supportive features, such as rapid eye movement sleep behavior
disorder. DLB is often misdiagnosed and unrecognized in elderly individuals.
Design: A questionnaire, designed to cover the main DLB symptoms, according to consensus criteria from
the third report of the DLB Consortium from 2005, was distributed in 40 NHs. The questionnaires were
completed by the nursing staff after receiving speciﬁcally designed teaching. Medication lists were
collected from the Swedish national medication dispensing system.
Setting: Nursing homes.
Participants: Of 650 eligible residents, 620 (96%) were included. The mean age was 86.0  7.5 years; 467
(75%) were women.
Results:We found a prevalence of 16% of 2 or more main symptoms of DLB in the NH residents. However,
when a wider more inclusive parkinsonism variable was used, the prevalence of DLB symptoms
increased to 20%.
Conclusion: We conclude that elderly with 2 or more DLB symptoms may constitute between 16% and
20% of all residents in NHs. This emphasizes the importance of identiﬁcation of DLB and guides clinicians
to deliver appropriate treatment for this fragile patient group.
 2016 AMDA e The Society for Post-Acute and Long-Term Care Medicine. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).In 2010, there were 35.6 million people living with dementia
worldwide and costs were estimated to be US$602 billion.1 Alzheimer
dementia, the most common neurodegenerative disorder, accounts
for approximately 60% of all dementia2 and the second most common
neurodegenerative disorder is dementia with Lewy bodies (DLB), with
hallmarks such as parkinsonism, visual hallucinations, ﬂuctuating
cognition, and rapid eye movement (REM) sleep behavior disorder
(RBD). Nevertheless, DLB is often misdiagnosed and unrecognized.3,4
Classical epidemiological studies of DLB are scarce, leading to
limited information about DLB prevalence. Systematic reviews showGovernmental Funding of
es (ALF), Swedish Research
’s Foundation, and Kockska
mory Clinic, Skåne University
ic).
and Long-Term Care Medicine. Ththat the prevalence of DLB varies between 15% and 25% in autopsy
series and 0% to 30.5% in clinical studies of elderly with dementia.5,6
However, these neuropathological populations are highly selected
and therefore not generalizable. Prevalence studies on DLB and elderly
in nursing homes (NHs) are missing. However, earlier studies from
NHs have shown that the prevalence of Parkinson disease (PD) was 5%
and the actual Lewy body pathology was present in 20% of elderly
residents.7,8
Several studies emphasize the importance of clinical staging of
DLB, as well as ﬁnding these patients earlier so as to reduce the risk of
wrong diagnoses, unsuitable medication, worsening of quality of life,
early NH admission, and, ﬁnally, avoiding the increased risk of shorter
survival.9e11
A diagnosis of DLB is important for several reasons: ﬁrst, because of
the risk of hypersensitivity for antipsychotics and risk for shorter
survival,12 and second, because medical treatments with cholines-
terase inhibitors (ChEI) and with the N-methyl-D-aspartate receptor
antagonist (memantine) have shown positive effects on visual hallu-
cinations, global improvement, and cognition, followed by reducedis is an open access article under the CC BY-NC-ND license (http://creativecommons.
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ChEI and memantine is a well-tolerated treatment with few adverse
effects.18,19 Additionally, low doses of Parkinson medication can be
useful when motor symptoms are present.20
The aims of this study were to identify and estimate the prevalence
of DLB symptoms in a population covering all dementia NHs in a large
Swedish city of 320,000 citizens.
Methods
The Study Population
Malmö is the third largest city in Sweden with 320,000 in-
habitants. From January 2012 to March 2013 there were 40 NHs,
speciﬁcally for dementia residents, which were contacted for partic-
ipation in this study. Presentations and seminars were given by a
resident physician (IZ) to all nursing personnel in each NH separately
before start.
The Questionnaire
The questionnaire covered main DLB symptoms (parkinsonism,
recurrent visual hallucinations, ﬂuctuating cognition) and suspected
RBD.
To facilitate for the nursing staff to recognize the DLB character-
istics, we chose observable signs with no need of medical examina-
tion: parkinsonism (rigidity, stiffness, tremor and/or a rigid posture
and walk, and weak voice) and for ﬂuctuating cognition (excessive
tiredness, sleeps in daytime, variations in attention and wakefulness),
REM sleep disorder (acting out dreams during sleep, shouting out at
night) (Figure 1). The questionnaire was presented in detail to all
nursing staff, by a resident physician (IZ) separately, in small groups
for 2 hours, to obtain reliable answers. Later the questions of the actualThe person from the nursing home has : YES NO
Parkinson´s disease or parkinsonism
Rigidity: symptoms of stiffness, tremor and/or a 
rigid posture and walk.
Weak voice
Balance problems: dizziness/faints/falling easier 
and/or more frequently
Visual hallucinations: describes conscious 
apparitions 
Excessive daytime sleepiness: variations in 
attention and wakefulness
Sleep disorder: acting out dreams during sleep 
(sometimes violently), shouting out at night.
Nightmares.
Usage of Parkinson’s medication
Usage of Antipsychotics
Stroke (cerebral hemorrhage/cerebral infarct) 
Medical list attached
Fig. 1. The questionnaire presents 7 main DLB symptoms plus information on stroke
(cerebral hemorrhage/cerebral infarct) and usage of Parkinson medication and
antipsychotics.presence of symptoms were answered as yes/no by the nursing staff
with the most knowledge about that resident (Figure 1).
Besides these clinical characteristics, we also collected de-
mographic information, such as age, gender, reported stroke, and
usage of antipsychotics and PD medication in the questionnaire. To
compare and validate the responses, we also collected medical lists,
from the same time period, from the Swedish national medication
dispensing system (NMDS). Four main DLB symptoms (parkinsonism,
visual hallucinations, ﬂuctuating cognition, and suspected RBD) were
used to form 2 groups; DLB0e1 (residents with none or 1 symptom)
and DLB2e4 (residents with 2 to 4 symptoms).The Deﬁnition of Parkinsonism
The stricter deﬁnition of parkinsonism included if PD or parkin-
sonismwas reported in the questionnaire and/or if PDmedicationwas
present in the medical list (Figure 1). However, to increase the
sensitivity of parkinsonism, we also used reported rigidity, weak voice,
and balance problems to create a more sensitive, wider, variable for
parkinsonism. This included PD or parkinsonism reported in the
questionnaire or PD medication according to the medical list or all 3
reported symptoms: rigidity, weak voice, and balance problems.
Thereafter, these stricter and wider parkinsonism variables together
with visual hallucinations, ﬂuctuating cognition, and suspected RBD,
respectively, were used to form the stricter and wider DLB groups.Statistical Analysis
For the statistical analysis, we used the IBM Statistical Package for
the Social Sciences (SPSS) for Windows (version 22.0; IBM Corpora-
tion, Armonk, NY).
For comparisons of 2 independent groups, the Student t test was
used for normally distributed data and the Mann-Whitney U test for
nonparametric data.
Categorical data were investigated using the c2 test. The signiﬁ-
cance level was set to P< .05. When comparing the distribution of age
groups (DLB0e1 and DLB2e4), analysis of variance (ANOVA)was used.Ethical Statement
Informed consent was obtained from the NH residents and/or their
caregivers before inclusion in the study. The Regional Ethical Review
Board in Lund approved this study.Results
Demographics
In this study, there were 650 elderly living in 40 NHs. Thirty
declined to enter the study or were in a stage of palliative treatment
(Figure 2). The response rate from the NHs was 98.3%. Kappa value, for
PD medication reported by nursing staff compared with PD medica-
tion in the NMDS was 0.94 (P < .001).
The mean age in the 620 eligible elderly who participated was 86
(7.5) years, with a range from 58 to 105 years. Fifty percent of the
residents were between the ages of 80 and 89 years. In the total study
population, most were women 467 (75%) (Table 1). Furthermore, in
the groups DLB0e1 and DLB2e4, there was no difference in gender,
regardless of use of the stricter or wider deﬁnition of parkinsonism.
We did ﬁnd a difference in gender (11% men and 6% women) in the
individuals with the highest number (3 or 4) of DLB symptoms.
Declined
N=30
Total population 
40 nursing homes
N=650 
Residents with 2-4 
DLB main symptoms
N=100 (16%)
Missing
N=31
Diagnoses from medical journals
N=69
Alzheimer
N=28(41%)
Dementia NOS 
N=19(27%)
DLB/PDD
N=13(19%)
VaD
N=9(13%)
Study population 
N=620 
Residents with 0-1
DLB main symptoms
N=520 (84%)
Fig. 2. Flow chart of the study population from January 2012 to March 2013, geographically covering the entire population of all dementia NHs (n ¼ 40) in the third largest city in
Sweden. Thirty declined to enter the study or were in a stage of palliative treatment. Due to missing data from medical journals (n ¼ 31) excluded.
I. Zahirovic et al. / JAMDA 17 (2016) 706e711708DLB Symptoms
Parkinsonism according to the stricter parkinsonism deﬁnitionwas
present in 42 (7%). Among these, 25 (4%) also had weak voice, balance
problems, and rigidity.
Parkinsonism according to the wider parkinsonism deﬁnition was
found in 90 (14%) of all residents and in 49 (49%) from the DLB2e4
group (Table 2).
The most prevalent DLB symptoms were ﬂuctuating cognition
(89%), visual hallucinations (79%), suspected RBD (48%), and parkin-
sonism (34%) (Table 2).The prevalence of the 4main DLB symptoms is presented in a Venn
diagram showing the overlap between the symptoms (Figure 3).
Of 620 residents, 319 had no DLB symptoms. The most prevalent
combination of only 2 DLB symptoms were visual hallucinations and
ﬂuctuating cognition (n ¼ 30). The combination of 3 features with
most residents were visual hallucinations, ﬂuctuating cognition plus
suspected RBD (n ¼ 20). The combination with all 4 symptoms was
present in 8 residents.
Among residents with parkinsonism, almost one-third (29%) had
suspected RBD, two-thirds (69%) had ﬂuctuating cognition, and 55%
had visual hallucinations. Seventy-nine (64%) of the residents with
Table 1
Demographics
All Elderly n (%)
620 (100)
DLB0e1* n (%)
520 (83.8)
DLB2e4y n (%)
100 (16.2)
Age, y
n 619 519 100
Mean 85.7 85.9 84.5
Median 87 87 85
SD 7.5 7.5 7.4
MineMax 58e105 58e105 62e100
Pz 0.082
Age group (%)
<70 22 (4) 17 (3) 5 (5)
70e74 33 (5) 27 (5) 6 (6)
75e79 45 (7) 37 (7) 8 (8)
80e84 143 (23) 114 (22) 29 (29)
85e89 172 (28) 144 (28) 28 (28)
>90 204 (33) 180 (35) 24 (24)
Px .048
Pk <.001
Sex, n (%)
Male 153 (25) 125 (82) 28 (18)
Female 467 (75) 395 (85) 72 (15)
Min, minimum; Max, maximum.
*DLB0e1, none or 1 DLB symptom.
yDLB2e4, 2 or more DLB symptoms.
zComparison of mean age in DLB0e1 and DLB2e4. P ¼ .082 (T-test).
xComparison of mean age for all age groups. P ¼ .048 (ANOVA).
kComparison of mean age in >90 in DLB0e1 and DLB2e4. P < .001 (Mann-
Whitney).
Fig. 3. Overlapping of main DLB symptoms. P, parkinsonism; H, visual hallucinations;
F, ﬂuctuating cognition; D, dreams/sleep behavior disorder.
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ﬂuctuating cognition, or suspected RBD) (Figure 3).
Stroke (cerebral hemorrhage/cerebral infarct) was reported in 117
elderly (24%) and equally distributed in the DLB0e1 and DLB2e4
groups (Table 2).
Prevalence
Sixteen percent of the residents had 2 ormoremain DLB symptoms
(DLB2e4) and 20% when the wider parkinsonism deﬁnitionwas used.
Thus, the total prevalence of elderly with DLB symptoms varied in the
stricter and wider DLB2e4 groups between 16% and 20% (Table 2).
Furthermore, with access to the medical journals, we found de-
mentia diagnoses in 69 residents in the DLB2e4 group distributed as
Alzheimer disease in 41%, Dementia Not Otherwise Speciﬁed (NOS) in
27%, DLB/PD with dementia (PDD) in 19%, and vascular dementia
(VaD) in 13% (Figure 2).Table 2
Clinical Characteristics by the Questionnaire for DLB Symptoms
All Elderly n (%)
620 (100)
Clinical features/Core features
Visual hallucinations 123 (20)
EDS/ﬂuctuating cognition 232 (37)
Parkinsonian features
Parkinson, stricter 42 (7)
Parkinson, wider 90 (14)
Rigidity 203 (33)
Balance 245 (39)
Weak voice 133 (22)
Supportive features
Sleep disorder/suspected RBD 55 (9)
Exclusive features
Strokez 117 (24)
EDS, excessive daytime sleepiness.
*DLB0e1, none or 1 DLB symptom.
yDLB2e4, 2 or more DLB symptoms.
zN ¼ 496 (100%); 379 without stroke and 117 residents with stroke.Discussion
In this large study of 620 elderly in 40 NHs, the prevalence of 2 or
more main DLB symptoms was 16% to 20%. These results correspond
well with previous studies that show DLB prevalence in both clinical
and pathological studies between 15% and 22%.7,21,22 Among residents
with 2 to 4 main DLB symptoms, only 19% had a formal DLB/PDD
diagnosis, again suggesting that this might be an underrecognized
condition (Figure 2).
In previous studies, it has been suggested that the DLB diagnosis is
most often found in elderly who are older than 80 years.22,23 Themean
age of the residents in our study was 86 years, indicating that our
study population was suitable for investigating Lewy body symptoms,
as Lewy body pathology increases with age.24
According to a clinical study on DLB prevalence in a Finnish pop-
ulation, 70% of the patients with a DLB diagnosis were in the age group
80 to 89.22 In our study, we found similar results, where approxi-
mately two-thirds of the residents in the DLB2e4 group were in the
same age group. A French study showed similar results, with the
highest DLB incidence rate in elderly who are older than 85 years.25
In many studies, there is a gender difference, with men having a
higher prevalence of DLB compared with women.18,26 In our study,
there was no signiﬁcant difference in frequency between men (18%)
and women (15%) in the group DLB2e4 (Table 1). One of the reasons
may be that our study population has a high mean age, whereas
previous studies have shown higher prevalence of DLB in men in the
age group 70 to 79 and more equal prevalence in age groups older
than 80 years.24,27,28 However, we did ﬁnd a signiﬁcant difference in
gender among individuals with 3 to 4 DLB symptoms (11%men and 6%DLB0e1* n (%)
520 (84)
DLB2e4y n (%)
100 (16)
P
44 (8) 79 (79) <.001
143 (27) 89 (89) <.001
8 (2) 34 (34) <.001
41 (8) 49 (49) <.001
138 (27) 65 (65) <.001
176 (27) 69 (69) <.001
83 (16) 50 (50) <.001
7 (1) 48 (48) <.001
96 (23) 21 (28) .18
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older residents in the study, there was a signiﬁcantly higher frequency
of men with 3 to 4 DLB symptoms, those most likely having possible
DLB.
By analyzing the questionnaires in more detail, we found that 25
(4%) of the residents with strict parkinsonism also had a concomitant
occurrence of the 3 speciﬁc symptoms (weak voice, balance problems,
and rigidity). In a Norwegian study, the prevalence of PD in NHs, in
clinically examined elderly, was 5%, which is comparable to our results
where parkinsonism was present in 4% of the residents.8
In earlier studies, parkinsonism has been found to be present in
55% to 60% of patients with DLB. In our study, we found parkinsonism
in 34%.22,29 This may reﬂect one of our limitations; that is, not being
able to perform clinical examinations of the residents, and therefore
underestimating parkinsonism. However, using the wider parkin-
sonism variable showed that in the DLB2e4 group, half (49%) of all
residents had some parkinsonian feature. This may suggest that the
symptoms of weak voice, balance problems, and rigidity improved the
identiﬁcation of parkinsonism and possible DLB.
RBD, incorporated in the latest DLB criteria, is an important
symptom in patients with DLB.4,23 In our study, we found suspected
RBD in 48% of the elderly, which compared with other studies on
dementia patients. This is most presumably an underestimation
because it is difﬁculty to identify.30 Possible RBD is sometimes
described as an early symptom of DLB and it might thus have dis-
appeared when assessed in our study population of older age.
The prevalence of ﬂuctuating cognition in the DLB2e4 group of
89% corresponds well with frequencies of 77% to 91% in earlier
studies.12,22,29
Visual hallucinations were present in two-thirds of the residents
in combination with another DLB symptom, as shown in our ques-
tionnaire and the Venn diagram. Furthermore, the combination of 2
symptoms that comprised most residents were hallucinations and
ﬂuctuating cognition (13%), supported by other studies in which the
prevalence of these 2 symptoms together were the most found
combination.31 As ﬂuctuating cognition is often seen in combination
with other symptoms, questioning about ﬂuctuating cognition is a
possible opening in the clinical history taking, and questions about
visual hallucinations and vivid dreams and neurological investiga-
tion regarding parkinsonism should follow. This could improve
recognition and reduce the risk of underestimating patients with
DLB.
Visual hallucinations were shown in 20% of all the residents and
occurred in more than two-thirds (79%) of all the elderly in the group
DLB2e4. Other studies show a wide range (40%e63%) of visual hal-
lucinations for patients with DLB.12,22,28,30 This may reﬂect that the
presence of hallucinations is a clinical symptom that is difﬁcult to
examine in DLB because many patients have good insight and do not
admit this symptom.
In our study, 64% had hallucinations in combinationwith other DLB
symptoms.
When visual hallucinations coexist with symptoms such as RBD,
cognitive ﬂuctuations, and episodic confusion, they can be difﬁcult to
identify and subsequently difﬁcult to treat.32 Because the setting was
NHs for dementia, all the elderly fulﬁlled the basic dementia criterion
and therefore addition of speciﬁc signs of DLB could indicate a diag-
nosis of DLB.
Stroke was reported equally frequent in both DLB groups (DLB0e1
and DLB2e4), meaning that stroke was not a major variable contrib-
uting to the symptoms.
Our study has a number of strengths. First, the study and its
questionnaire with DLB symptoms were presented separately for each
of the 40 NHs. The presentation was given to all the nursing staff
involved in the study, and questionnaires were completed by the
nursing staff who had spent the most time observing the elderly andwere therefore able to observe small changes. This gave us valid in-
formation about the symptoms of the 620 residents. Second, access of
the computer-based medical lists from the Swedish NMDS for all the
residents (n ¼ 620) allowed us to study the accuracy of the collected
material concerning medication in the study questionnaire.
An important limitation is that there is no measure of dementia
severity, as we were not able to diagnose the residents with clinical
examinations. The NH was designed for patients with dementia,
meaning that dementia severity was most often severe. The ques-
tionnaire was designed to facilitate the nursing staff in recognizing
observable signs of the DLB characteristics instead of the terminology
of these in the consensus criteria. Therefore, the questionnairewas not
tested for reliability or validity.
However, by setting strict criteria for the deﬁnition of the included
symptoms in the 2 DLB groups from the start of the study, we believe
that the identiﬁed group is not overestimated. This, together with the
high response frequency, quality of questionnaires, and computerized
medical lists, makes the result of 16% to 20% prevalence of DLB
plausible.Conclusion
We conclude that elderly with DLB symptoms may constitute be-
tween 16% and 20% of all residents in NHs. This result reﬂects the
importance of the identiﬁcation of DLB by general practitioners and
could help clinicians to be able to deliver a more appropriate treat-
ment for this fragile patient group.Acknowledgments
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